Phathom Pharmaceuticals financials
$7.36+0.14%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 |
|---|---|---|---|---|---|---|---|
| Revenue | $175.1M | $55.3M | $682.0K | $0.00 | — | — | — |
| Gross profit | $152.5M | $47.3M | $515.0K | $0.00 | — | — | — |
| Gross margin | 87.1% | 85.6% | 75.5% | — | — | — | — |
| Operating income | -$160.0M | -$277.5M | -$167.3M | -$172.4M | -$135.1M | -$125.7M | -$106.2M |
| Net income | -$221.2M | -$334.3M | -$201.6M | -$197.7M | -$143.9M | -$129.1M | -$255.1M |
| Net margin | −126.3% | −605.1% | −29558.9% | — | — | — | — |
| Diluted EPS | $-3.03 | $-5.29 | $-3.93 | $-5.05 | $-3.89 | $-3.88 | $-22.45 |
| EBITDA | -$159.4M | -$276.7M | -$166.7M | -$171.8M | -$134.6M | -$125.3M | -$106.2M |
| Operating cash flow | -$166.8M | -$266.8M | -$137.6M | -$146.5M | -$148.5M | -$69.7M | -$61.6M |
| Free cash flow | -$167.0M | -$266.9M | -$139.2M | -$147.6M | -$148.8M | -$70.7M | -$61.8M |
| Diluted shares | 72.9M | 63.2M | 51.3M | 39.1M | 37.0M | 33.2M | 11.4M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $130.0M | $297.3M | $381.4M | $155.4M | $183.3M | $287.5M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $210.9M | $203.1M | $139.0M | $96.1M | $90.1M | $47.3M |
| Total assets | $259.1M | $378.3M | $413.8M | $164.8M | $189.4M | $295.1M |
| Total liabilities | $697.3M | $631.9M | $486.6M | $239.6M | $117.3M | $100.8M |
| Shareholders' equity | -$438.2M | -$253.6M | -$72.8M | -$74.8M | $72.2M | $194.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology